Literature DB >> 8591936

Bactericidal in-vitro activity of beta-lactams and beta-lactamase inhibitors, alone or associated, against clinical strains of Acinetobacter baumannii: effect of combination with aminoglycosides.

M L Joly-Guillou1, D Decré, J L Herrman, E Bourdelier, E Bergogne-Bérézin.   

Abstract

Five Acinetobacter baumannii strains of various phenotypes were selected on the basis of the results of a national survey in France in 1991. beta-Lactamases in Acinetobacter isolates were characterized by isoelectrofocusing. We carried out a 24 h time-kill study to assess the bactericidal effect of antibiotic alone or in combination against A. baumannii strains. The initial inoculum was 10(6) cfu/mL. Antibiotics were tested at MIC x 2 when an antibiotic was tested alone and at the MIC for each combination including ticarcillin, piperacillin, ceftazidime or imipenem with or without amikacin or netilmicin and/or beta-lactamase inhibitors. Concentration of inhibitors were: 2 mg/L for clavulanic acid, 4 mg/L for tazobactam and 8 mg/L for sulbactam. Sulbactam and tazobactam showed an intrinsic in-vitro activity against strains susceptible to ticarcillin. A complete killing at 24 h was observed when beta-lactams were combined with amikacin in comparison with antibiotics alone. Synergy was lost when the strain presented a low resistance level to beta-lactams or aminoglycosides except for ticarcillin. Combinations of sulbactam with ticarcillin showed the best bactericidal activity against strains multiresistant to beta-lactams.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8591936     DOI: 10.1093/jac/36.4.619

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

1.  Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii.

Authors:  Rajbharan Yadav; Cornelia B Landersdorfer; Roger L Nation; John D Boyce; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

2.  In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model.

Authors:  M Wolff; M L Joly-Guillou; R Farinotti; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

3.  In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak.

Authors:  M D Appleman; H Belzberg; D M Citron; P N Heseltine; A E Yellin; J Murray; T V Berne
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

4.  Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii.

Authors:  X Corbella; A Montero; M Pujol; M A Domínguez; J Ayats; M J Argerich; F Garrigosa; J Ariza; F Gudiol
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

Review 5.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

6.  SPR741, an Antibiotic Adjuvant, Potentiates the In Vitro and In Vivo Activity of Rifampin against Clinically Relevant Extensively Drug-Resistant Acinetobacter baumannii.

Authors:  Daniel V Zurawski; Alexandria A Reinhart; Yonas A Alamneh; Michael J Pucci; Yuanzheng Si; Rania Abu-Taleb; Jonathan P Shearer; Samandra T Demons; Stuart D Tyner; Troy Lister
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

7.  Multidrug-resistant Acinetobacter baumannii strains with NDM-1: Molecular characterization and in vitro efficacy of meropenem-based combinations.

Authors:  Jingjing Wang; Yongzhong Ning; Shu Li; Yun Wang; Jinhua Liang; Chunming Jin; Hairun Yan; Yongcun Huang
Journal:  Exp Ther Med       Date:  2019-08-20       Impact factor: 2.447

8.  The minimal inhibitory concentration for sulbactam was not associated with the outcome of infections caused by carbapenem-resistant Acinetobacter sp. treated with ampicillin/sulbactam.

Authors:  Maura S de Oliveira; Silvia Figueiredo Costa; Ewerton de Pedri; Inneke van der Heijden; Anna Sara S Levin
Journal:  Clinics (Sao Paulo)       Date:  2013-04       Impact factor: 2.365

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.